CN111903965A - Composition with liver-protecting and eye-protecting effects and preparation method and application thereof - Google Patents
Composition with liver-protecting and eye-protecting effects and preparation method and application thereof Download PDFInfo
- Publication number
- CN111903965A CN111903965A CN202010706410.3A CN202010706410A CN111903965A CN 111903965 A CN111903965 A CN 111903965A CN 202010706410 A CN202010706410 A CN 202010706410A CN 111903965 A CN111903965 A CN 111903965A
- Authority
- CN
- China
- Prior art keywords
- parts
- roller
- hyaluronic acid
- liver
- protecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title claims description 21
- 238000001035 drying Methods 0.000 claims abstract description 64
- 240000007594 Oryza sativa Species 0.000 claims abstract description 58
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 57
- 235000009566 rice Nutrition 0.000 claims abstract description 57
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 51
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 51
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 51
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims abstract description 50
- 235000013312 flour Nutrition 0.000 claims abstract description 37
- 210000004185 liver Anatomy 0.000 claims abstract description 28
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 27
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 27
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 27
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 27
- 239000002245 particle Substances 0.000 claims abstract description 26
- 235000012754 curcumin Nutrition 0.000 claims abstract description 25
- 229940109262 curcumin Drugs 0.000 claims abstract description 25
- 239000004148 curcumin Substances 0.000 claims abstract description 25
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 25
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 24
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 24
- 235000008434 ginseng Nutrition 0.000 claims abstract description 24
- 235000006533 astragalus Nutrition 0.000 claims abstract description 23
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims abstract description 23
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 22
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 22
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 15
- 230000002633 protecting effect Effects 0.000 claims abstract description 14
- 239000007788 liquid Substances 0.000 claims abstract description 4
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- 238000012216 screening Methods 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 230000036541 health Effects 0.000 claims description 32
- 238000002156 mixing Methods 0.000 claims description 31
- 239000000084 colloidal system Substances 0.000 claims description 27
- 239000008213 purified water Substances 0.000 claims description 26
- 239000002002 slurry Substances 0.000 claims description 26
- 241000208340 Araliaceae Species 0.000 claims description 24
- 238000000227 grinding Methods 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 16
- 235000013305 food Nutrition 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 9
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 6
- 229940014041 hyaluronate Drugs 0.000 claims description 6
- 235000011837 pasties Nutrition 0.000 claims description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 229960005069 calcium Drugs 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 3
- 238000004537 pulping Methods 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 3
- 235000021436 nutraceutical agent Nutrition 0.000 claims 3
- 238000007790 scraping Methods 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 6
- 239000002244 precipitate Substances 0.000 abstract description 3
- 230000006378 damage Effects 0.000 abstract description 2
- 241000411851 herbal medicine Species 0.000 abstract description 2
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 238000005054 agglomeration Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 26
- 239000000463 material Substances 0.000 description 23
- 241001122767 Theaceae Species 0.000 description 20
- 235000012149 noodles Nutrition 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 241001061264 Astragalus Species 0.000 description 8
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 8
- 206010013774 Dry eye Diseases 0.000 description 8
- 238000010186 staining Methods 0.000 description 8
- 210000004233 talus Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 235000013402 health food Nutrition 0.000 description 6
- 230000001953 sensory effect Effects 0.000 description 6
- 206010067125 Liver injury Diseases 0.000 description 5
- 235000004879 dioscorea Nutrition 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000003908 liver function Effects 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000019423 liver disease Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000533950 Leucojum Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000010835 comparative analysis Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000008935 nutritious Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- -1 saponin compounds Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 208000035197 Disorder of carbohydrate metabolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 208000020450 carbohydrate metabolism disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009044 synergistic interaction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/79—Schisandraceae (Schisandra family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition with the effects of protecting liver and eyes, which is characterized by comprising, by weight, 10-40 parts of hyaluronic acid, 20-60 parts of Chinese yam, 3-15 parts of ginseng, 2-10 parts of astragalus membranaceus, 2-10 parts of schisandra chinensis, 2-10 parts of curcumin, 3-10 parts of chitosan oligosaccharide and 3-10 parts of tea polyphenol. According to the invention, hyaluronic acid and Chinese yam with specific molecular weights are compounded in a proper proportion, and the liver-protecting and eye-protecting component is added to prepare rice flour, so that the problems of limited addition amount of hyaluronic acid, more precipitates, poor taste, easiness in agglomeration during brewing and the like caused by more Chinese herbal medicine components in the liver-protecting and eye-protecting component when the hyaluronic acid is prepared into oral liquid, tablets and brewing powder particles are solved, and the formula has the advantages of good tabletting effect, strong toughness, easiness in scraping and no damage to the tablets during roller drying.
Description
Technical Field
The invention relates to the field of medicines, common foods or health-care foods, in particular to a composition with the effect of protecting liver and eyes and a preparation method and application thereof.
Background
The liver has close relationship with eyes, and when the liver is diseased, the function of the eyes can be affected and even eye diseases can be caused: the liver is an organ with most vitamin A in a human body, and the liver disease causes the reduction of the level of the vitamin A in blood plasma, which leads to the reduction of the sensitivity to weak light and the weakening of the sunlight adaptability; abnormal liver function causes disorder of carbohydrate metabolism, and hyperglycemia may cause dry eye.
The rice paste prepared by roller drying has good mixing property and taste, and the product produced by the process is not easy to cause excessive internal heat, so that the rice paste has good market prospect.
The roller drying process researched and developed in recent years has various food types, for example, CN109892547A discloses a wet preparation method of an instant nutritious corn snowflake tablet, and CN109892551A discloses a wet preparation method of an instant nutritious chenopodium quinoa snowflake tablet.
CN1726803 discloses an instant rice flour for infants and its preparation method, wherein the raw materials are rice, rhizoma Nelumbinis, and sucrose, and the rice flour is prepared by pulverizing, mixing, blending, colloid milling, and drying, and the invention is directed to the formulation of serial products.
The raw materials of common rice flour and rice paste in the prior art mainly comprise rice, millet and corn, and the raw materials provide certain viscosity for a roller drying process, so that the slurry can form a sheet on the surface of a drying roller in the drying process, but the toughness, the viscosity, the smoothness and the taste of the product are poor.
Disclosure of Invention
Aiming at the problems, the invention provides a composition with the effect of protecting liver and eyes, which comprises 10-40 parts by weight of hyaluronic acid, 20-60 parts by weight of Chinese yam, 3-15 parts by weight of ginseng, 2-10 parts by weight of astragalus, 2-10 parts by weight of schisandra chinensis, 2-10 parts by weight of curcumin, 3-10 parts by weight of chitosan oligosaccharide and 3-10 parts by weight of tea polyphenol.
Further, the composition comprises 15-30 parts of hyaluronic acid, 30-50 parts of Chinese yam, 5-10 parts of ginseng, 4-8 parts of astragalus membranaceus, 5-10 parts of schisandra chinensis, 2-6 parts of curcumin, 3-8 parts of chitosan oligosaccharide and 5-10 parts of tea polyphenol.
Further, the hyaluronic acid has a molecular weight of (0.5-1.5). times.106Da, preferably (0.8-1.2). times.106Da。
Specifically, the hyaluronic acid includes, but is not limited to, one or more of hyaluronic acid, sodium hyaluronate, calcium hyaluronate and magnesium hyaluronate.
The invention also provides application of the composition in preparing medicines, health-care foods or common foods with the liver and eye protection effects. The liver and eye protecting effect includes treating dry eye.
The invention also provides a medicine, health-care food or common food containing the composition with the liver-protecting and eye-protecting effects. The health food can be selected from rice flour.
The invention also provides a preparation method of the health food, wherein the health food is selected from health rice flour, and the method comprises the following steps:
mixing hyaluronic acid, rhizoma Dioscoreae, Ginseng radix, radix astragali, fructus Schisandrae chinensis, curcumin, chitosan oligosaccharide, and tea polyphenols, adding purified water, mixing, and stirring;
grinding the stirred slurry into thick liquid by a colloid mill;
pre-pasting the pulp after pulping on a pre-pasting roller;
the pasty raw material formed by pre-gelatinization is carried to the surface of a drying roller for drying;
and (4) crushing and screening the flakes scraped from the drying roller by using a crushing and screening machine.
Further, the surface temperature of the pre-gelatinization roller is kept at 140 ℃ and 145 ℃.
Furthermore, the amount of the used purified water is 2-3 times of the total raw material mass.
Further, the particle size of the colloid mill screen used was 150 mesh.
Further, the moisture after drying is not higher than 4%. The drying conditions are as follows: the rotating speed of the roller is 8-10r/min, and the surface temperature of the roller is kept at 125-130 ℃.
Furthermore, the fineness of the screen mesh of the crushing and screening machine is 4-8 mm.
The invention uses hyaluronic acid and yam to replace traditional cereals such as rice and the like as main components for providing viscosity in the process, and additionally adds components for protecting liver and eyes, and the product has the effects that:
(1) according to the invention, hyaluronic acid and Chinese yam with specific molecular weights are compounded in a proper proportion, and the liver-protecting and eye-protecting component is added to prepare rice flour, so that the problems of limited hyaluronic acid addition amount, more precipitates, poor mouthfeel, easy caking and the like caused by more Chinese herbal medicine components in the liver-protecting and eye-protecting component when the liver-protecting and eye-protecting component is prepared into oral liquid, tablets and reconstituted powder particles are solved;
(2) in the invention, hyaluronic acid with specific molecular weight and Chinese yam are compounded in a proper proportion to replace the traditional five cereals as main components for providing viscosity in a roller drying process, so that the slurry has good sheeting effect and strong toughness, is easy to scrape off and cannot cause sheet damage in the roller drying process;
(3) in the invention, hyaluronic acid with specific molecular weight and Chinese yam are compounded in a proper proportion, so that the obtained rice flour has better viscosity, smooth feeling and reconstitution property;
(4) according to the invention, the hyaluronic acid can reduce the loss of efficacy of the efficacy component under the high-temperature condition, and the raw materials can be synergistically enhanced, so that the efficacy of the product is greatly improved.
Drawings
FIG. 1 is a flow chart of a preparation method of the health rice flour I.
Detailed Description
The invention provides a composition with the effect of protecting liver and eyes and a health-care food with the effect of protecting liver and eyes, and further researches are carried out on the influence of the selection of raw materials on the drying process, the viscosity, the mixing property and the smooth feeling of a product.
The embodiments described below in connection with the drawings are described in detail with the understanding that the present invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
The invention provides health-care rice flour with the effects of protecting liver and eyes, which comprises hyaluronic acid, Chinese yam, ginseng, astragalus, schisandra chinensis, curcumin, chitosan oligosaccharide and tea polyphenol.
Wherein, the hyaluronic acid is macromolecular chain polysaccharide which is regularly and repeatedly formed by D-glucuronic acid and N-acetylglucosamine disaccharide units, and has higher content in organs such as skin, joint cavity, eyes, and the like.
The yam contains rich nutrient components such as crude protein, crude fiber, iron, potassium and the like, and the yam polysaccharide can improve the mouse liver injury caused by carbon tetrachloride by removing free radicals.
Ginseng radix is a medicinal plant of Panax of Araliaceae, has high medicinal value, and has effects of invigorating primordial qi, invigorating spleen, benefiting lung, promoting fluid production, tranquilizing mind, and improving intelligence. Ginsenoside shows good treatment effect in various liver diseases, and mainly regulates liver function by resisting oxidation and inflammation and inhibiting cytochrome P450.
The astragalus contains astragalus polysaccharide, saponin compounds, flavonoid compounds and the like, and the astragalus polysaccharide can enhance the oxidation resistance of the liver of a rat with hyperlipidaemia, reduce total cholesterol of the liver, increase the activity of SOD (superoxide dismutase) of the liver and glutathione peroxidase, and has a certain effect of protecting the liver.
Fructus Schisandrae chinensis is mature dry fruit of Schisandra chinensis Baill of Magnoliaceae, and its extract and various monomer components have therapeutic effect on liver diseases caused by alcoholic liver injury, non-alcoholic liver injury, hepatic fibrosis, etc.
Curcumin is an active ingredient of turmeric, is a polyphenol substance, and can achieve the effects of blocking and delaying the pathological process of liver injury by removing liver free radicals, inhibiting liver inflammatory reaction and inhibiting liver collagen synthesis.
The chitosan oligosaccharide is an oligosaccharide formed by connecting 2-10 glucosamine through beta-1, 4-glycosidic bonds, and has the obvious effects of reducing blood fat, preventing fatty liver and protecting liver.
The tea polyphenol is an active ingredient extracted from tea, has various biological activities of scavenging free radicals, resisting oxidation and the like, and has an obvious protective effect on an experimental liver injury model.
The invention provides a composition with the effect of protecting liver and eyes, which comprises 10-40 parts by weight of hyaluronic acid, 20-60 parts by weight of Chinese yam, 3-15 parts by weight of ginseng, 2-10 parts by weight of astragalus membranaceus, 2-10 parts by weight of schisandra chinensis, 2-10 parts by weight of curcumin, 3-10 parts by weight of chitosan oligosaccharide and 3-10 parts by weight of tea polyphenol.
Further, the composition comprises 15-30 parts of hyaluronic acid, 30-50 parts of Chinese yam, 5-10 parts of ginseng, 4-8 parts of astragalus membranaceus, 5-10 parts of schisandra chinensis, 2-6 parts of curcumin, 3-8 parts of chitosan oligosaccharide and 5-10 parts of tea polyphenol.
Specifically, the hyaluronic acid may be 15 parts, 20 parts, 25 parts, 30 parts, or any range therebetween, by weight part;
the yam may be 30, 35, 40, 45, 50 parts or any range therebetween.
The ginseng may be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, or any range therebetween.
The astragalus may be 4 parts, 5 parts, 6 parts, 7 parts, 8 parts or any range therebetween.
The schisandra chinensis can be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts or any range therebetween.
The curcumin may be 2 parts, 3 parts, 4 parts, 5 parts, 6 parts, or any range therebetween.
The chitosan oligosaccharide may be 3 parts, 4 parts, 5 parts, 6 parts, 7 parts, 8 parts or any range therebetween.
The tea polyphenol may be 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts or any range therebetween.
Further, the hyaluronic acid has a molecular weight of (0.5-1.5). times.106Da, preferably (0.8-1.2). times.106Da。
Specifically, the hyaluronic acid includes, but is not limited to, one or more of hyaluronic acid, sodium hyaluronate, calcium hyaluronate and magnesium hyaluronate.
The invention also provides application of the composition in preparing medicines, health-care foods or common foods with the liver and eye protection effects. The liver and eye protecting effect includes treating dry eye.
The invention also provides a medicine, health-care food or common food containing the composition with the liver-protecting and eye-protecting effects. The health food can be selected from rice flour.
The invention also provides a preparation method of the health food, as shown in figure 1, the health food is selected from health rice flour, wherein the health rice flour is prepared by the following steps:
mixing hyaluronic acid, Chinese yam, ginseng, astragalus mongholicus, schisandra chinensis, curcumin, chitosan oligosaccharide and tea polyphenol uniformly, adding purified water for size mixing, and stirring uniformly, wherein the amount of the purified water is 2-3 times of the total raw material weight;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pasty raw material formed by pre-gelatinization is carried to the surface of a drying roller for drying until the moisture is not higher than 4%, and the drying conditions are as follows: the rotating speed of the roller is 8-10r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the slices scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen mesh of the crushing and screening machine is 4-8 mm.
The manufacturers of the raw materials and equipment used in the present example, and the equipment and analysis method used in the product analysis are described below, wherein the chemical substances are not indicated as being chemically pure grades of conventional reagents. The information on the raw materials used in the examples is shown in Table 1.
Table 1 information on the raw materials used in the examples
| Raw material information | Type/purity | Manufacturer of the product |
| Hyaluronic acid | The purity is 99.9 percent | BLOOMAGE BIOTECH Co.,Ltd. |
| Chinese yam | The purity is 99.2 percent | ANHUI SUNHERE PHARMACEUTICAL EXCIPIENTS Co.,Ltd. |
| Ginseng radix | Puffed powder | SHAANXI SCIPHAR NATURAL PRODUCTS Co.,Ltd. |
| Radix astragali | Puffed powder | SHAANXI SCIPHAR NATURAL PRODUCTS Co.,Ltd. |
| Schisandra chinensis | Puffed powder | SHAANXI SCIPHAR NATURAL PRODUCTS Co.,Ltd. |
| Curcumin (curcumin) | Purity 95% | Red date Biotechnology Limited by Schchen Tai |
| Chitosan | BZ/purity 90.0% | QINGDAO BZ OLIGO BIOTECH Co.,Ltd. |
| Tea polyphenols | The purity is 99.0 percent | Jianxi Jiahe Biotech Co Ltd |
Example 1 preparation of health rice flour
Molecular weight of 1.0X 10625 parts of Da hyaluronic acid, 40 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus membranaceus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the used purified water is 2.5 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 9r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 5 mm.
Example 2 preparation of health rice flour
Molecular weight of 1.2X 10625 parts of Da hyaluronic acid, 30 parts of Chinese yam, 10 parts of ginseng, 8 parts of astragalus membranaceus, 5 parts of schisandra chinensis, 6 parts of curcumin, 3 parts of chitosan oligosaccharide and 5 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 3 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 10r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 4 mm.
Example 3 preparation of health rice flour
Molecular weight of 0.8X 10630 parts of Da hyaluronic acid, 50 parts of Chinese yam, 5 parts of ginseng, 4 parts of astragalus membranaceus, 10 parts of schisandra chinensis, 2 parts of curcumin, 8 parts of chitosan oligosaccharide and 10 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 5 mm.
Example 4 preparation of health rice flour
Molecular weight of 0.5X 10615 parts of Da hyaluronic acid, 45 parts of Chinese yam, 9 parts of ginseng, 7 parts of astragalus membranaceus, 9 parts of schisandra chinensis, 3 parts of curcumin, 4 parts of chitosan oligosaccharide and 6 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 3 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 5 mm.
EXAMPLE 5 preparation of health Rice noodles
Molecular weight of 1.5X 10620 parts of Da hyaluronic acid, 40 parts of Chinese yam, 7 parts of ginseng, 5 parts of astragalus, 8 parts of schisandra chinensis, 5 parts of curcumin, 6 parts of chitosan oligosaccharide and 7 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the used purified water is 2.5 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 5 mm.
Comparative example 1 preparation of ordinary health rice flour
Taking 40 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the total mass of the materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
and (3) crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen of the crushing and screening machine is 5 mm.
Comparative example 2 preparation of ordinary health rice flour
Molecular weight of 1.8X 10625 parts of Da hyaluronic acid, 40 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus membranaceus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen mesh of the crushing and screening machine is 5 mm;
comparative example 3 preparation of ordinary health rice flour
Molecular weight of 0.3X 10625 parts of Da hyaluronic acid, 40 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus membranaceus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen mesh of the crushing and screening machine is 5 mm;
comparative example 4 preparation of ordinary health rice flour
Molecular weight of 1.0X 10625 parts of Da hyaluronic acid, 20 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus membranaceus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen mesh of the crushing and screening machine is 5 mm;
comparative example 5 preparation of ordinary health rice flour
Molecular weight of 1.0X 10625 parts of Da hyaluronic acid, 60 parts of Chinese yam, 8 parts of ginseng, 6 parts of astragalus membranaceus, 7 parts of schisandra chinensis, 4 parts of curcumin, 5 parts of chitosan oligosaccharide and 8 parts of tea polyphenol, uniformly mixing, adding purified water for size mixing, and uniformly stirring, wherein the amount of the purified water is 2 times of the mass of the total materials;
grinding the above slurry with colloid mill, wherein the colloid mill has a screen mesh with particle size of 150 mesh;
pre-gelatinizing the slurry after the pulp grinding on a pre-gelatinizing roller, and keeping the surface temperature of the roller at 140-145 ℃;
the pre-gelatinized material is taken into the surface of a drying roller to be dried until the moisture is not higher than 4 percent, and the drying conditions are as follows: the rotating speed of the roller is 8r/min, and the surface temperature of the roller is kept at 125-;
crushing and screening the flaky objects scraped from the drying roller by using a crushing and screening machine to obtain the health-care rice noodles meeting the particle size requirement, wherein the fineness of a screen mesh of the crushing and screening machine is 5 mm;
TABLE 2 Components and parts used in the examples and comparative examples
Description of the drawings: "/" indicates that the starting material was not added during the preparation.
Experimental example 1 analysis of results of roller drying Process
The results of observing the flaking effect, wall sticking and scraping of the materials during the drying process in examples S1, S2, S3, S4 and S5 and comparative examples C1, C2, C3, C4 and C5 were shown in Table 3, and the thickness of the flakes was measured with a vernier caliper (precision 0.01mm, Shanghai tool works Co., Ltd.) and, if the flakes were thin, they affected the state during the rinsing with water and were liable to cake and have poor rinsing properties.
TABLE 3 different health rice flour roller drying results
| Sheet thickness (mm) | Sheeting effect | Scraping out situation | |
| S1 | 0.31 | Whole piece without breaking | Easy to scrape off |
| S2 | 0.30 | Whole piece without breaking | Easy to scrape off |
| S3 | 0.30 | Whole piece without breaking | Easy to scrape off |
| S4 | 0.28 | Whole piece without breaking | Easy to scrape off |
| S5 | 0.30 | Whole piece without breaking | Easy to scrape off |
| C1 | 0.20 | Fracture of | With chippings |
| C2 | 0.29 | Fracture of | Is not easy to scrape off |
| C3 | 0.21 | Fracture of | With chippings |
| C4 | 0.20 | Fracture of | With chippings |
| C5 | 0.30 | Fracture of | Is not easy to scrape off |
As can be seen from the above table, the health rice flour obtained in the examples has large thickness, good flaking effect and is easy to scrape, while the health rice flour obtained in the comparative examples has small thickness, poor flaking effect and is difficult to scrape.
Comparative example 1 was compared with example 1 except that comparative example 1 was not added with hyaluronic acid, and example 1 was added with a molecular weight of 1.0X 106Da of 25 parts of hyaluronic acid, the difference in the roller drying process is very large, and the sheet thickness of example 1 is 0.31mm, which is a whole sheet, is not broken and is easy to scrape off in the drying process, while the sheet thickness of comparative example 1 is only 0.20mm, and the sheet is broken and has scraps when being scraped off.
Compared with example 1, the difference between comparative example 2 and example 1 is that the molecular weight of hyaluronic acid used in comparative example 2 is higher, the difference between the slicing effect and the scraping condition of the health rice flour prepared in example 1 and comparative example 2 is larger, the slice in example 1 is not broken and is easy to scrape in the drying process, and the slice in comparative example 2 is broken and is not easy to scrape.
Comparing comparative example 3 with example 1, the difference is that hyaluronic acid used in comparative example 3 has a lower molecular weight, the thickness, the flaking effect and the scraping condition of the health rice noodles prepared in example 1 and comparative example 3 are greatly different, the flake of example 1 is not broken and is easy to scrape in the drying process, the flake thickness reaches 0.31mm, the flake thickness of comparative example 3 is only 0.21mm, and the flake has breakage and is chipped when being scraped. Therefore, when the molecular weight of the hyaluronic acid is controlled within a certain range, the material can reach a better thickness in the drying process, and the flake shape is not broken and is easy to scrape.
Comparing comparative example 4 with example 1, the thickness, the flaking effect and the scraping condition of the health rice noodles prepared in example 1 and comparative example 4 are greatly different, the thickness of the flake obtained in comparative example 4 is only 0.21mm, the flake is broken and the flake is scraped.
Compared with the example 1, the health rice flour prepared in the example 1 and the health rice flour prepared in the comparative example 5 have larger difference of the sheeting effect and the scraping condition, and the rice flour sheet obtained in the comparative example 5 is broken and is not easy to scrape. Therefore, when the dosage of the Chinese yam is in a certain range, the material can reach a better thickness in the drying process, and the Chinese yam slices are not cracked and are easy to scrape.
In conclusion, when the components in the embodiment of the invention are within a certain range, the obtained health-care rice flour has good cohesiveness and flaking effect in the drying process and is easy to scrape.
Experimental example 2 sensory evaluation result analysis
Sensory evaluation was conducted on samples of examples S1, S2, S3, S4, S5 and comparative examples C1, C2, C3, C4, and C5 by a sensory panel of 30 persons, each score was 10 points, and the results were shown in Table 4, respectively, in terms of product morphology, taste and texture, stickiness, smoothness, and reconstitution properties.
TABLE 4 different health rice flour sensory results analysis
As can be seen from table 4, the total sensory evaluation scores of S1, S2, S3, S4 and S5 are higher than those of C1, C2, C3, C4 and C5, wherein C1 has lower product morphology, taste and mouthfeel, viscosity, smooth feeling and reconstitution performance score due to the fact that hyaluronic acid is not added; c2 and C5 have high viscosity and smooth taste scores, but have poor shape, taste and mouthfeel, and low total score; the thickness of the products C3 and C4 can not be reached, and the product shape, taste and mouthfeel, viscosity, smoothness and taste and brewing performance score are lower. The obtained health rice flour has optimal shape, taste, viscosity, smoothness and mixing property only when the content of each component is controlled within a certain range.
Experimental example 3 analysis of results of rehydration Rate and rehydration time
The rehydration rate and rehydration time of the samples of examples S1, S2, S3, S4, S5 and comparative examples C1, C2, C3, C4, C5 were determined and directly appear to affect the reconstitution properties of the rice flour product, with the results shown in table 5.
And (3) measuring the rehydration rate: weighing 4g of sample, placing the sample in a pre-weighed centrifugal tube, gradually adding water, stirring the sample uniformly by using a glass rod every 1 time of adding water until the sample becomes pasty, wiping the glass rod on the tube wall, centrifuging at 2000r/min, adding water if no supernatant is available, stirring uniformly, and repeating until a small amount of supernatant exists. The rehydration rate is [ (centrifuge tube mass + precipitate mass) - (centrifuge tube mass + sample mass) ]/sample mass.
Determination of rehydration time: 2g of the sample was placed in an insulated container with a lid, 10mL of hot water at 80 ℃ was added, the container was immediately capped while counting by a stopwatch, and was tightened and softened by a glass plate, and when no hard core was observed, the time taken was recorded.
TABLE 5 rehydration rates and rehydration times for different health rice noodles
As can be seen from table 5, the rehydration time of the obtained rice flour is lower than that of C1, C3, C4 and C5 and the rehydration rate is higher than that of C1, C3, C4 and C5 because S1, S2, S3, S4 and S5 are compounded with hyaluronic acid and yam with specific molecular weight and content to protect liver and eyes, presumably because C1, C3 and C4 are thin, and are easy to agglomerate when being brewed by adding water, the rehydration of agglomerated parts is slow, so that the rehydration time is long and the rehydration rate is low; the hyaluronic acid used in C2 has a high molecular weight and can rapidly absorb water, but is poor in sensory evaluation form, taste and mouthfeel and reconstitution property in combination with experimental example 2, and thus is not a preferred embodiment as a whole; c5 has high content of rhizoma Dioscoreae, and has long rehydration time and low rehydration rate when adding water for brewing. The above shows that when the content of each component is controlled within a certain range, the rehydration rate and the rehydration time of the obtained health rice flour can reach better levels.
Experimental example 4 measurement of Dry eye ameliorating Effect
1. Experimental methods
A total of 550 patients with dry eye were selected as subjects. The subjects were randomly divided into 11 groups, 5 groups and 6 groups of controls, the experimental groups were administered 10g each of S1, S2, S3, S4 and S5 samples per day, and the controls were administered 10g each of C1, C2, C3, C4, C5 and C6 (hyaluronic acid powder, 1.0X 10)6Da) samples of 10g each were taken once a day for 4 weeks, and the observation was continued for 2 weeks after the cessation of the administration.
2. Observation indicator and method
The product was observed 1 time before and after use.
(1) And (3) safety detection: blood routine, urine routine, liver function, kidney function, electrocardiogram.
(2) And (3) observation of curative effect: the clinical symptoms are: fatigue, discomfort, foreign body sensation, dryness, burning sensation, and vision fluctuation; II, SIT test; thirdly, BUT detection; fourthly, dyeing with ocular surface fluorescein: dividing the cornea into 4 quadrants and dividing the cornea into 3 grades; no coloration, small area coloration, large area coloration.
3. Criteria for therapeutic effect
The treatment effect is judged according to the traditional Chinese medicine disease diagnosis treatment effect standard: firstly, curing: disappearance of symptoms, regression of corneal staining, more than 5min > 10mm for SIT multiple measurements, or more than 10s for BUT measurements; improvement: reduced symptoms, reduced corneal staining, increased tear secretion when measured multiple times by SIT or prolonged BUT; ③ not cured: no improvement in symptoms, no change or increase in corneal staining, no increase in tear secretion when measured multiple times by SIT or no prolongation of BUT time.
4. Results
(1) Comparison of clinical efficacy
The results of clinical efficacy in 11 dry eye patients are shown in Table 6.
The table shows that the total effective rate of S1, S2, S3, S4 and S5 reaches 96%, 94%, 96%, 92% and 94%, and the total effective rate of C1, C2, C3, C4, C5 and C6 reaches 64%, 80%, 82%, 84%, 86% and 62%.
Total effective rate (cure case number + number of improvement cases)/total case number 100%
TABLE 6 comparison of clinical efficacy
| Group of | Number of examples | Cure of disease | Improvement of life | Not cured | Total effective rate/%) |
| S1 | 50 | 8 | 40 | 2 | 96.0 |
| S2 | 50 | 7 | 40 | 3 | 94.0 |
| S3 | 50 | 8 | 40 | 2 | 96.0 |
| S4 | 50 | 7 | 39 | 4 | 92.0 |
| S5 | 50 | 7 | 40 | 3 | 94.0 |
| C1 | 50 | 1 | 31 | 18 | 64.0 |
| C2 | 50 | 3 | 37 | 10 | 80.0 |
| C3 | 50 | 4 | 37 | 10 | 82.0 |
| C4 | 50 | 45 | 37 | 8 | 84.0 |
| C5 | 50 | 5 | 38 | 7 | 86.0 |
| C6 | 50 | 0 | 31 | 19 | 62.0 |
(2) Comparison of SIT and BUT before and after treatment
The results of clinical efficacy in 11 dry eye patients are shown in Table 7.
As shown in the table, the groups S1, S2, S3, S4 and S5 have significant differences in SIT and BUT values before and after treatment (P is less than 0.01); BUT values of the C4 and C5 groups are also significantly different before and after treatment (P is less than 0.05); the SIT and BUT values of the C1, C2, C3 and C6 groups are different before and after treatment, BUT the SIT and BUT values of the C2 and C3 groups are larger than those of the C1 and C6 groups before and after treatment.
TABLE 7 comparative analysis of SIT and BUT before and after treatment
*P＜0.05，**P is less than 0.01; compared with the prior treatment and the subsequent treatment, the treatment has significant difference
(3) Comparison of corneal staining after treatment
The results of clinical efficacy in 11 dry eye patients are shown in Table 8.
As shown in the table, after treatment, the cornea fluorescein staining of the eyes of the groups S1, S2, S3, S4, S5, C4 and C5 is obviously improved; and after the treatment of the groups C1, C2, C3 and C6, the change of the corneal fluorescein staining of the eyes is not obvious.
TABLE 8 comparative analysis of corneal staining after treatment
| Group of | Number of examples | Without coloring | Coloring of small areas | Large area coloring |
| S1 | 50 | 11 | 35 | 4 |
| S2 | 50 | 10 | 35 | 5 |
| S3 | 50 | 11 | 35 | 4 |
| S4 | 50 | 12 | 33 | 5 |
| S5 | 50 | 10 | 33 | 7 |
| C1 | 50 | 1 | 30 | 19 |
| C2 | 50 | 5 | 32 | 13 |
| C3 | 50 | 6 | 32 | 12 |
| C4 | 50 | 8 | 32 | 10 |
| C5 | 50 | 7 | 34 | 9 |
| C6 | 50 | 2 | 28 | 20 |
(4) Adverse reaction
In the treatment process, 11 groups of patients have no abnormal changes in the aspects of blood routine, urine routine, liver and kidney functions and electrocardiogram.
5. Conclusion
The experimental result 4 shows that the patent sample can effectively improve the ocular surface symptoms, increase the lacrimal secretion amount, prolong the tear film rupture time, reduce the corneal staining, realize the synergistic interaction among the raw materials, and is an effective prescription for treating xerophthalmia. The hyaluronic acid with specific molecular weight and the Chinese yam are compounded in a proper proportion, so that the loss of efficacy of the efficacy components under a high-temperature condition can be further reduced, and the clinical total effective rate of a preferred scheme is more than 90%.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. The composition with the effects of protecting liver and eyes is characterized by comprising, by weight, 10-40 parts of hyaluronic acid, 20-60 parts of Chinese yam, 3-15 parts of ginseng, 2-10 parts of astragalus membranaceus, 2-10 parts of schisandra chinensis, 2-10 parts of curcumin, 3-10 parts of chitosan oligosaccharide and 3-10 parts of tea polyphenol.
2. The composition of claim 1, wherein the composition comprises, by weight, 15-30 parts of hyaluronic acid, 30-50 parts of Chinese yam, 5-10 parts of ginseng, 4-8 parts of astragalus membranaceus, 5-10 parts of schisandra chinensis, 2-6 parts of curcumin, 3-8 parts of chitosan oligosaccharide and 5-10 parts of tea polyphenol.
3. The composition of claim 1, wherein the hyaluronic acid has a molecular weight of (0.5-1.5) x 106Da, preferably (0.8-1.2). times.106Da。
4. The composition according to claim 1, wherein the hyaluronic acid comprises one or more of hyaluronic acid, sodium hyaluronate, calcium hyaluronate, magnesium hyaluronate.
5. Use of the composition of any one of claims 1 to 4 for the preparation of a pharmaceutical, nutraceutical or food product having liver and eye protecting effects.
6. A pharmaceutical, health-care or food product comprising the composition for liver and eye protection according to any one of claims 1 to 4.
7. The pharmaceutical, nutraceutical, or food product of claim 6, wherein the nutraceutical is selected from health rice flour.
8. The method of preparing a health product according to claim 7, said health product being selected from the group consisting of health rice flour, the method comprising:
mixing hyaluronic acid, rhizoma Dioscoreae, Ginseng radix, radix astragali, fructus Schisandrae chinensis, curcumin, chitosan oligosaccharide, and tea polyphenols, adding purified water, mixing, and stirring;
grinding the stirred slurry into thick liquid by a colloid mill;
pre-pasting the pulp after pulping on a pre-pasting roller;
the pasty raw material formed by pre-gelatinization is carried to the surface of a drying roller for drying;
and (4) crushing and screening the flakes scraped from the drying roller by using a crushing and screening machine.
9. The method for preparing a health product according to claim 8,
the surface temperature of the pre-gelatinization roller is kept at 140 ℃ and 145 ℃.
10. The method for preparing a health product according to claim 8,
the amount of the used purified water is 2-3 times of the total raw material mass;
the particle size of the colloid mill screen is 150 meshes;
the moisture after drying is not higher than 4%; the drying conditions are as follows: the rotating speed of the roller is 8-10r/min, and the surface temperature of the roller is kept at 125-;
the fineness of the screen mesh of the crushing and screening machine is 4-8 mm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010706410.3A CN111903965B (en) | 2020-07-21 | 2020-07-21 | Composition with liver-protecting and eye-protecting effects and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010706410.3A CN111903965B (en) | 2020-07-21 | 2020-07-21 | Composition with liver-protecting and eye-protecting effects and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111903965A true CN111903965A (en) | 2020-11-10 |
| CN111903965B CN111903965B (en) | 2022-08-16 |
Family
ID=73281515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010706410.3A Active CN111903965B (en) | 2020-07-21 | 2020-07-21 | Composition with liver-protecting and eye-protecting effects and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111903965B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113940969A (en) * | 2021-10-13 | 2022-01-18 | 湖北小仙品山药保健酒业有限公司 | Pretreatment device for preparing Chinese yam hyaluronic acid oral liquid and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104585763A (en) * | 2015-01-28 | 2015-05-06 | 广西博科药业有限公司 | Liver-protecting and liver-nourishing functional food and preparation method thereof |
| CN108066496A (en) * | 2016-11-15 | 2018-05-25 | 威海紫光科技园有限公司 | A kind of protect liver Chinese medicine and health food |
| CN108125124A (en) * | 2018-01-30 | 2018-06-08 | 无锡宝通科技股份有限公司 | A kind of ourishing rice flour and preparation method thereof |
| CN110876772A (en) * | 2019-12-12 | 2020-03-13 | 森隆药业有限公司 | Preparation method and application of traditional Chinese medicine preparation with liver protection function |
-
2020
- 2020-07-21 CN CN202010706410.3A patent/CN111903965B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104585763A (en) * | 2015-01-28 | 2015-05-06 | 广西博科药业有限公司 | Liver-protecting and liver-nourishing functional food and preparation method thereof |
| CN108066496A (en) * | 2016-11-15 | 2018-05-25 | 威海紫光科技园有限公司 | A kind of protect liver Chinese medicine and health food |
| CN108125124A (en) * | 2018-01-30 | 2018-06-08 | 无锡宝通科技股份有限公司 | A kind of ourishing rice flour and preparation method thereof |
| CN110876772A (en) * | 2019-12-12 | 2020-03-13 | 森隆药业有限公司 | Preparation method and application of traditional Chinese medicine preparation with liver protection function |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113940969A (en) * | 2021-10-13 | 2022-01-18 | 湖北小仙品山药保健酒业有限公司 | Pretreatment device for preparing Chinese yam hyaluronic acid oral liquid and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111903965B (en) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | Purified Auricularia auricular-judae polysaccharide (AAP Ia) prevents oxidative stress in an ageing mouse model | |
| CN105077236B (en) | Compound special meals nutrient powder of the highland barley of auxiliary hyperglycemic and preparation method thereof | |
| KR20230057438A (en) | Compositions of ginsenosides Rg3 and ginsenosides Rg5 and pharmaceutical uses thereof, including antitumor effects | |
| CN103298477A (en) | Composition comprising cudrania tricuspidata and coix lachryma-jobi having an obesity-suppressing activity and blood-sugar lowering effect, and a use therefor | |
| CN104784505B (en) | A kind of Dendrobium officinale health product of auxiliary hyperglycemic and preparation method thereof | |
| CN108157575A (en) | A kind of pressed candy for alleviating visual fatigue and preparation method and application | |
| CN105343636B (en) | A kind of medicine-food dual-purpose composition and preparation method thereof with hypolipemic function | |
| CN111903965B (en) | Composition with liver-protecting and eye-protecting effects and preparation method and application thereof | |
| Wu et al. | New insight into the joint significance of dietary jujube polysaccharides and 6-gingerol in antioxidant and antitumor activities | |
| CN109400750B (en) | Pharmaceutical composition with uric acid reducing effect | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN103349675A (en) | Medical use of vegetable soybeans in diabetes prevention and treatment | |
| CN106177432A (en) | A kind of health composition comprising leaf of Cyclocarya paliurus Iljinskaja, Folium Mori, green tea and Rhizoma Polygonati Odorati | |
| CN110731509A (en) | A health product containing prebiotics for lowering blood sugar and blood lipid, and its preparation method | |
| CN105327115B (en) | A kind of prevention and treatment type II diabetes Phellinus is logical to rush down formula and preparation process | |
| CN114947127A (en) | Health food composition for improving immunity of tumor patients and preparation method and application thereof | |
| CN104013696B (en) | A kind of plant drug composition of preventing and treating metabolism syndrome and its application | |
| TWI712417B (en) | Composition for moistening bowel and laxative and its application and functional food | |
| CN105641672A (en) | Composition for treating obesity caused by energy metabolism imbalance and preparation | |
| RU2812611C1 (en) | Compositions of ginsenoside rg3 and ginsenoside rg5 and their pharmaceutical uses, including antitumor effects | |
| CN105617319A (en) | Preparation method of traditional Chinese medicine composition for treating acute cholecystitis | |
| CN108295187A (en) | Improve the soft capsule preparation and preparation method thereof of immunity | |
| CN114869930B (en) | Silver bar powder for traditional Chinese medicine composition and preparation process and application thereof | |
| CN107898972A (en) | A kind of Chinese medicine composition and application for being used to treat liver diseases | |
| CN111686210B (en) | Composition with anti-laryngeal cancer activity and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230613 Address after: Tianchen Avenue, Ji'nan hi tech Development Zone of Shandong Province, No. 678 250101 Patentee after: BLOOMAGE BIOTECH Co.,Ltd. Address before: No. 3333, middle section of Century Avenue, hi tech Zone, Jinan City, Shandong Province Patentee before: SHANDONG BLOOMAGE HYINC BIOPHARM Corp.,Ltd. |